New hope for breast cancer brain metastases? drug combo trial launches

NCT ID NCT05872347

Recruiting now Disease control Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a new oral drug called SPH4336 combined with standard hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study aims to see if the combination can shrink brain tumors and control the disease. About 52 participants will be enrolled, and the main focus is on how well the treatment works inside the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPH4336 (a targeted drug taken orally) combined with endocrine therapy (letrozole, fulvestrant, or exemestane)
What this could lead to: If successful, this could offer a new treatment option for people with HR-positive, HER2-negative breast cancer that has spread to the brain, potentially shrinking or controlling brain tumors.
What could go wrong: This is an early Phase 2 trial with only 52 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BRAIN METASTASES

Contacts and locations

Locations

Affiliated Cancer Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510060, China
Anhui provincial hospital
RECRUITING

Hefei, Anhui, 230002, China
Anyang Cancer Hospital
RECRUITING

Anyang, He'nan, 455001, China
Beijing Cancer Hospital
RECRUITING

Beijing, China
Cancer Hospital of Xinjiang Medical University
RECRUITING

Ürümqi, Xinjiang, 830054, China
Chongqing University Three Gorges Hospital
RECRUITING

Chongqing, 404031, China
General Hospital of Ningxia Medical University
RECRUITING

Yinchuan, Ningxia, 750003, China
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
RECRUITING

Nanning, China
Harbin Medical University cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210029, China
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, 130012, China
Liuzhou people's Hospital
RECRUITING

Liuzhou, Guangxi, 545026, China
Peking Union Medical College Hospital
RECRUITING

Beijing, 100730, China
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, 230022, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, China
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING

Luoyang, He'nan, 450052, China
The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050011, China
The first hospital of Jilin University
RECRUITING

Changchun, Jilin, 130061, China
The second people's hospital of neijiang
RECRUITING

Neijiang, Sichuan, 641199, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, China
Xi'An International Medical Cancer Hospital
RECRUITING

Xi'an, China
Xiangyang Central Hospital
RECRUITING

Xiangyang, Hubei, 441021, China
Zhejiang cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310005, China